New Delhi: A day after Congress attacked PM Modi over his visit to vaccine facilities amid ongoing farmers’ protests, senior party leader Anand Sharma showered praises on the prime minister and asserted that his visit was a recognition of Indian scientists and their work to produce vaccines for coronavirus. Notably, Anand Sharma was part of the group of 23 Congress leaders who wrote the “dissent letter” that had caused a rift within the party in August. Also Read - Israeli Rabbi Makes Bizarre Claim, Tells His Followers That COVID-19 Vaccine Will Turn People Gay
“Prime Minister Shri Narendra Modi visit to Serum Institute, Bharat Biotech and Zydus Cadila was a recognition of Indian scientists and their work to produce the vaccine for Covid-19. That alone will lift morale of frontline warriors and reassure the nation,” Anand Sharma said in a tweet. Also Read - PM Modi Performs Bhoomi Pujan of Ahmedabad, Surat Metro Rail Projects | All You Need to Know
Shortly, he issued a clarification and said he regrets the error in his earlier tweets “where the lines got misplaced, resulting in some avoidable confusion”. Also Read - Coronavirus Vaccine Side-Effects: Don't Freak Out if You Experience These Issues in Your Body After Getting Vaccinated
“Prime Minister Shri Narendra Modi visit to Serum Institute, Bharat Biotech and Zydus Cadila was a recognition of Indian scientists and their work to produce the vaccine for COVID-19. This is acknowledging and respecting the institutions that India has built over decades that have expertise and potential making India world’s largest vaccine manufacturer (sic),” Sharma said, according to the revised content of the tweet posted by him.
“Urging PM to ensure that an efficient and equitable platform is functional as the vaccine arrives. This alone will lift the morale of frontline COVID warriors and reassure the nation (sic),” he said.
Earlier on Saturday, Prime Minister Modi had visited Zydus Biotech Park in Ahmedabad, Bharat Biotech in Hyderabad and Serum Institute of India (SII) in Pune to review the development and manufacturing process of coronavirus vaccines at facilities in these cities.